Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15916220 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL605463 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL1162359 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL145000 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL5043328 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL2065907 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL3363663 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| Bromide SCHEMBL9771320 | 0.98 | KDM4E (0.54) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| Hydrochloric Acid SCHEMBL9779186 | 0.98 | ALDH1A1 (0.57) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| Benzoic Acid SCHEMBL6048463 | 0.87 | DAO (0.48) | KDM4EADRA2AADRA2CLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330004-B | Differential solubility driven asymmetric conversion process for substituted 2H-chromene-3-carboxylic acids | 株式会社AskAt | 2023-11-17 | — | — | CN | claimed |
| EP-3906232-B1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC (JP) | 2023-05-10 | — | — | EP | claimed |
| EP-3906232-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | AskAt Inc. (JP) | 2021-11-10 | — | — | EP | claimed |
| CN-113330004-A | Differential solubility driven asymmetric transformation process for substituted 2H-chromene-3-carboxylic acids | 株式会社AskAt | 2021-08-31 | — | — | CN | claimed |
| US-11065238-B2 | Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2021-07-20 | — | — | US | claimed |
| WO-2020153279-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2020-07-30 | — | — | WO | claimed |
| US-9833768-B2 | Affinity reagents for protein purification | IMPOSSIBLE FOODS INC. (US) | 2017-12-05 | — | — | US | claimed |
| US-20170320041-A1 | AFFINITY REAGENTS FOR PROTEIN PURIFICATION | IMPOSSIBLE FOODS INC. | 2017-11-09 | — | — | US | claimed |
| US-9737875-B2 | Affinity reagents for protein purification | IMPOSSIBLE FOODS INC. (US) | 2017-08-22 | — | — | US | claimed |
| US-20130143824-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-20120058953-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20110039324-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2011-02-17 | — | — | US | claimed |
| US-20090148921-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. (US) | 2009-06-11 | — | — | US | claimed |
| EP-1590666-B1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2008-07-09 | — | — | EP | claimed |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | claimed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171554-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. | 2004-09-02 | — | — | US | claimed |
| EP-0398288-B1 | Process for preparing optically active 2-arylalkanoic acids, in particular 2-arylpropionic acids | PUETTER MEDICE CHEM PHARM (DE) | 1995-10-18 | — | — | EP | claimed |
| US-5380927-A | Process for preparing optically active 2-aryl-alkanoic acids, in particular 2-aryl-propionic acids | MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) | 1995-01-10 | — | — | US | claimed |
| EP-0398288-A2 | Process for preparing optically active 2-arylalkanoic acids, in particular 2-arylpropionic acids | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1990-11-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | SOST, PTMS, FGF23 | KDM4E 3668/4885ADRA2A 4343/4885ADRA2C 4227/4885 |
| US-11065238-B2 | Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases | GBA1, SMN1; SMN2, GAA | KDM4E 3898/4885ADRA2A 4123/4885ADRA2C 4133/4885 |
| US-20170320041-A1 | AFFINITY REAGENTS FOR PROTEIN PURIFICATION | RAB5IF, MRPL21, RPS27A | KDM4E 3795/4885ADRA2A 4513/4885ADRA2C 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.